Market Overview

The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

Here's a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

The following biotech stocks hit 52-week highs Jan. 10: 

  • Takeda Pharmaceutical Co Ltd (NYSE: TAK*)
  • Veracyte Inc (NASDAQ: VCYT)

None of the biotech stocks hit 52-week lows Thursday.

Stocks In Focus

Agile Confident In Twirla Approval By Year's End 

Agile Therapeutics Inc (NASDAQ: AGRX) said it expects to complete the comparative wear study for Twirla in the first quarter and resubmit the NDA in the first half of 2019. This renders a potential approval timeframe of the end of 2019.

Twirla is Agile's investigational low-dose, once-weekly contraceptive patch. The FDA previously issued a complete response letter to Agile's NDA for Twirla in December 2017.

The announcement followed the company's meeting with FDA's Division of Bone, Reproductive, and Urologic Products, where it discussed the specific design and success criteria of the comparative wear study intended to demonstrate adequate adhesion via non-inferiority of Twirla to Xulane, a generic version of the Ortho Evra contraceptive patch.

The company said it has sufficient cash to meet its projected operating requirements into Q2. 

The stock rose 1.57 percent to 80 cents in after-hours trading Thursday.

Advaxis Results Trail Expectations

Advaxis, Inc. (NASDAQ: ADXS) reported a decline in its 2018 revenue from $12.03 million a year ago to $6.06 million. The net loss narrowed from $2.31 to $1.29 as the company reined in expenses.

Analysts expected a loss of $1.09 per share on revenue of $6.28 million for the year.

Ocular Therapeutix Files For Expanded Indication For Eye Pain Drug

Ocular Therapeutix Inc (NASDAQ: OCUL) said it has submitted a sNDA for Dextenza, seeking an expansion in indication to include the treatment of ocular inflammation following ophthalmic surgery.

Dextenza was approved in November to treat post-surgical ocular pain for up to 30 days with a single administration. It is a preservative-free ophthalmic insert meant to be placed in the lower lacrimal punctum and into the canaliculus of the eye.

The company expects the review of the sNDA to be completed in the second half of the year. 

The stock rallied 2.5 percent to $4.10 in after-hours trading Thursday.

Related Links:

The Week Ahead In Biotech: Conferences, Clinical Trials

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Posted-In: Biotech Earnings News FDA Trading Ideas Best of Benzinga


Related Articles (ADXS + AGRX)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Aphria CEO, Co-Founder To Stand Down; Q2 Revenue Surges, But Trails Consensus

Jim Cramer Gives His Opinion On Cleveland-Cliffs, SINA, Take-Two And More